Stock Ratings / Health Care / GRML / insiders

CGTX (43) CRDF (41) NMRA (42) CSBR (22) ⌘ Pro Terminal →

Greenland Mines Ltd. (GRML) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$5.14 -5.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.08

Greenland Mines Ltd. (GRML) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $70.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRML Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $5.14 (-5.69% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRML compare to CGTX and CRDF in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRML?

▼

Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.08 (-1.21%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRML)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY GRML SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 39 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.17+16.1% Next Q

Q2 (-2Q)

Grade E$6.00-3.7% Next Q

Q3 (-1Q)

Grade E$5.78-11.1% Next Q

Current

Grade E$5.14-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRML Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRML currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.60) and Max Pain ($5.40) forces dealer call-delta covering toward $38.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRML• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GRML Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

GRML Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (GRML)

No recent open-market Form 4 cluster sales or emergency dumps flagged on GRML. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRML)

✓Walkthrough of GRML's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GRML // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.67%📐 HORIZONTAL RANGE

2026-10-30O $5.00H $5.14L $4.35C $5.14VOL 1.36M

RES: $18.74SUP: $-0.50SMA50: $6.60SMA200: $13.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRML Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRML Butterfly Map → + Track GRML →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRML today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRML. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GRML today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRML)

Health Care Rank #780 of 1016 ⚔️ CGTX vs GRML Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRML vs. CGTX, CRDF, NMRA, CSBR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenland Mines Ltd. (GRML) ranks #780 by composite RQD confidence (32/100, grade E) and #706 by equity capitalization ($70.3M). Within this direct 5-issuer industry benchmark cohort, GRML leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with GRML at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GRML ACTIVE Greenland Mines Ltd.	E	32/100	—	—	-35.0%	-5.69%	$70.3M	Benchmark Subject
CGTX Cognition Therapeutics Inc.	D-	43/100	—	—	-35.0%	-1.28%	$70.3M	/cgtx-vs-grml →
CRDF Cardiff Oncology Inc.	D-	41/100	—	—	-35.0%	+1.60%	$70.9M	/crdf-vs-grml →
NMRA Neumora Therapeutics Inc.	D-	42/100	—	—	-35.0%	-1.22%	$73.0M	/nmra-vs-grml →
CSBR Champions Oncology Inc.	E	22/100	—	48.0%	-26.9%	-2.24%	$66.9M	/csbr-vs-grml →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001907223

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenland Mines Ltd. (GRML) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.6M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-99.9% YoY). On the balance sheet, GRML closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.6M	-$5.9M	-$5.9M	$9.6M	—
FY2024 (FY)	2024-12-31	$0	-$6.2M	-$2.9M	-$2.9M	$2.5M	—
FY2023 (FY)	2023-12-31	$0	-$707.5K	-$446.9K	-$446.9K	—	—

3. GRML Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GRML compare to CGTX and CRDF in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GRML?

Where is GRML trading relative to its 50-day, 200-day, and 52-week technical levels?

GRML last traded at $5.14 (-5.69% on volume of 861,968 shares), positioning the stock -22.12% below its 50-day simple moving average ($6.60) and -62.59% below its 200-day simple moving average ($13.74). Across its 52-week range of $2.82 to $37.00, GRML sits at the 6.8% percentile with a 14-day RSI of 39.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.50 to $5.78).

GRML Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are GRML insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies GRML leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: GRML RQD Cockpit GRML 12M Forecast GRML Earnings & Move GRML Dividends & DRIP GRML Insiders & 13F GRML Whale Options GRML Profit Sankey GRML News & Why